NASDAQ : RLMD

Relmada Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 3.58 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 381.88M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Details

NameRelmada Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees17
Founded2004
CeoSergio Traversa
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS75955J4022
Cusip75955J402
Cik0001553643
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Sergio Traversa M.B.A., Pharm.D.Chief Executive Officer and Director
Maged S. Shenouda M.B.A., R.Ph.Chief Financial Officer
Paul E. Kelly M.B.A.Chief Operating Officer and Director
Charles S. Ence CPA, M.B.A.Chief Accounting and Compliance Officer
Gina DiGuglielmoVice President and Head of Clinical Operations
Dr. Bipin K. Dalmia MBA, Ph.D.Chief Business Officer
Dr. Andrew CutlerSenior Clinical Development Advisor
Dr. Richard M. Mangano Ph.D.Consultant

Contact

Address2222 Ponce de Leon Blvd., Floor 3, Coral Gables, Florida 33134, United States
Phone786 629 1376
Websitehttps://www.relmada.com